KRAS and non-small cell lung carcinoma: Adagrasib (MRTX849), the second potent inhibitor of the KRAS G12C mutation, was also approved by the FDA in December 2022 for the treatment of KRAS G12C mutated locally advanced or metastatic NSCLC.